This article was downloaded by: [University of California, San Diego] On: 12 June 2015, At: 09:50 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lsyc20

Suptacia of Nour

Synthesis of New

Pyrazolo[1,5-α]quinazoline Derivatives

Dániel Kovács^a, Judit Molnár-Tóth^a, Gábor Blaskó^a, Imre Fejes^a & Miklós Nyerges^a

^a Servier Research Institute of Medicinal Chemistry, Budapest, Hungary

Accepted author version posted online: 22 Apr 2015.Published online: 22 Apr 2015.

To cite this article: Dániel Kovács, Judit Molnár-Tóth, Gábor Blaskó, Imre Fejes & Miklós Nyerges (2015) Synthesis of New Pyrazolo[1,5-α]quinazoline Derivatives, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 45:14, 1675-1680, DOI: <u>10.1080/00397911.2015.1040511</u>

To link to this article: <u>http://dx.doi.org/10.1080/00397911.2015.1040511</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>



Synthetic Communications[®], 45: 1675–1680, 2015 Copyright © Taylor & Francis Group, LLC ISSN: 0039-7911 print/1532-2432 online DOI: 10.1080/00397911.2015.1040511

SYNTHESIS OF NEW PYRAZOLO[1,5-α]QUINAZOLINE DERIVATIVES

Dániel Kovács, Judit Molnár-Tóth, Gábor Blaskó, Imre Fejes, and Miklós Nyerges

Servier Research Institute of Medicinal Chemistry, Budapest, Hungary

GRAPHICAL ABSTRACT



Abstract The reaction of various anthranilic acid derivatives or their esters with 4-oxotetrahydrothiophene-3-carbonitrile 2, 2-oxocyclopentanecarbonitrile (9, n=1) or 2-oxocyclohexanecarbonitrile (9, n=2) in ethanol under reflux conditions giving rise the formation of single products isolated in each case after simple filtration. The products were characterized as pyrazolo[1,5-a]quinazolin-5-ones 4 instead of the expected pyrazol-3-amines 3. These cascade condensation-intramolecular acylation processes generated in one-step reactions from simple starting materials novel heterocyclic scaffolds ready for further functionalization. The present synthetic protocol provides acceptable yields of new tetracyclic products in high purity.

Keywords Cascade reactions; heterocycles; pyrazoles

INTRODUCTION

During one of our ongoing medicinal chemistry programs, we intended to prepare a small library of 2-aryl-4,6-dihydrothieno[3,4-c]pyrazol-3-amine derivatives (3) using the known nucleophilic addition: cyclization domino reaction between the appropriate aryl-hydrazine derivatives (1) and 4-oxotetrahydrothiophene-3-carbonitrile (2) (Scheme 1).^[1] A large number of derivatives of this heterocycle are well described in the patent literature because of their interesting pharmacological

Received February 12, 2015.

Address correspondence to Miklós Nyerges, Servier Research Institute of Medicinal Chemistry, 7 Záhony utca., H-1031 Budapest, Hungary. E-mail: miklos.nyerges@hu.netgrs.com

Color versions of one or more of the figures in the article can be found online at www.tandfonline. com/lsyc.



Scheme 1. General synthesis of pyrazole amines.

properties that allow them to function as P2X7 receptor antagonists,^[2] inhibitors of PDE4^[3] or the TrkA kinase,^[4] antivirials,^[5] or modulators of nicotinic acetylcholine receptors.^[6] However, to date there is no example described for the reaction of 2-hydrazino-benzoic acids (1, R1=COOH), or their esters (1, R1=COOR) and 4-oxotetrahydrothiophene-3-carbonitrile **2** in such processes.

RESULTS AND DISCUSSION

The starting 2-hydrazino-benzoic acids or their esters **1** are commercially available; however, because of their relatively high price all of them were prepared in house from the corresponding anthranilic acid derivatives according to the procedures described in the literature.^[7,8] These acids or their esters were reacted with 4oxotetrahydrothiophene-3-carbonitrile **2** in ethanol under reflux. After 3 h heating a single product was isolated (via **6**, **7** and **8**) in each case after simple filtration. These products were characterized as 6,7-dihydro-5*H*,9*H*-thieno[3'4':3,4]pyrazolo[1,5-*a*] quinazolin-5-ones **4** instead of the expected thieno[3,4-*c*]pyrazol-3-amines **3** on the basis of their elemental analysis as well as infrared (IR), ¹H NMR, ¹³C NMR, and mass spectral (MS) analysis. The IR spectrum of **4** revealed the presence of a carbonyl stretching vibration band around 1680 cm⁻¹, for the lactam carbonyl group, and in the NMR spectra a newly formed amide was visible instead of the amine. This lactam **4** was later reduced to the corresponding amine **5**, which become the key compound for further diversification of this small compound library in our medicinal



Scheme 2. Reagents and conditions: (i) ethanol, reflux; (ii) BH₃, THF.

NEW PYRAZOLO[1,5-α]QUINAZOLINE DERIVATIVES

Entry	Hydrazine	\mathbb{R}^1	\mathbb{R}^2	R ³	\mathbb{R}^4	R ⁵	Product	Yield (%)	Product	Yield (%)
1	1a	CO ₂ H	Н	Н	Н	Н	4 a	74	5a	51
2	1b	CO_2H	Н	Н	Н	CH ₃	4b	9	5b	
3	1c	CO_2H	Н	CH_3	Н	Н	4c	43	5c	95
4	1d	CO_2H	Н	Н	CH_3	Н	4d	49	5d	
5	1e	CO_2CH_3	CH_3	Н	Н	Н	4e	15	5e	
6	1f	CO ₂ CH ₃	Н	OCH ₃	Н	Н	4f	56	5f	85
7	1 g	CO_2CH_3	Br	Н	Η	Н	4 g	9	5 g	

Table 1. The synthesized thieno[3',4'.3,4]pyrazolo[1,5-a]quinazoline derivatives

chemistry program (Scheme 2, Table 1). Among the products **5a**, **5c**, and **5f** were successfully prepared. In other cases, a complex mixture was observed during the reduction that lacked the desired products (**5b**, **5d**, **5e**, and **5g**).

The formation of the pyrazole ring in the reaction of a keto-cyanide 1 and arylhydrazine 2 is well documented in the literature. However, the intramolecular acylation of the pyrazolamine 8 usually requires more activated acid derivatives such as chloride in the presence of base (Scheme 3).

In the same way, refluxing a solution of 2-oxocyclopentanecarbonitrile (9, n = 1) or 2-oxocyclohexanecarbonitrile (9, n = 2) in ethanol with arylhydrazines 1 afforded a series of novel tetracyclic pyrazolo[1,5-*a*]quinazoline 10 derivatives in a single step (Scheme 4, Table 2). Then the lactam 10 was reduced to the corresponding amine 11 under the same conditions described previously. Besides the successful reactions of 11a-c, 11e, and 11f (Table 2), the products 11d, 11g, and 11h were not observed, probably due to the decomposition of the proper lactams under the applied reaction conditions.



Scheme 3. Proposed reaction mechanism of the formation of the new thieno[3',4'.3,4]pyrazolo[1,5-a] quinazoline derivatives.



Scheme 4. Reagents and conditions: (i) ethanol, reflux; (ii) BH₃, THF.

In conclusion, we report a cascade condensation-intramolecular acylation process generated in the reaction of cyclic ketocyanides **2** and 2-hydrazino-benzoic acids or their esters **1** ($\mathbf{R}^1 = \mathbf{CO}_2\mathbf{H}$ or $\mathbf{CO}_2\mathbf{M}\mathbf{e}$ accordingly) to afford novel heterocycles. The present synthetic protocol provides acceptable yields of new tetracyclic products in good purity. The bioactivity of the newly synthesized compounds will be published elsewhere.

EXPERIMENTAL

Preparation of 2-Hydrazino-benzoic Acids

The corresponding anthranilic acid (1 mmol) was suspended in hydrochloric acid (6 M, 2.4 ml) and cooled to -5° C. Sodium nitrite (1.1 mmol) was dissolved in water (0.4 ml) and added dropwise. The reaction mixture was stirred for 1 h at -5° C and then SnCl₂ · 2H₂O was added (0.451 g, 2 mmol dissolved in 0.6 ml of 6 M aqueous HCl). The product was precipitated, filtered, washed with water, and dried in vacuo. The product was used without any further purification (yield 64–100%).

Reaction of Hydrazines with α -Oxo-cyanides

The corresponding 2-hydrazino-benzoic acid or methyl-2-hydrazino-benzoate (1.1 mmol) and the α -oxo-cyano compound (1 mmol) were suspended in dry ethanol (5.5 ml) and refluxed for 3 h. After cooling, the product was precipitated, filtered, and dried in vacuo to yield (51–85%) the title products.

Entry	Hydrazine	n	\mathbb{R}^1	\mathbb{R}^2	R ³	\mathbb{R}^4	R ⁵	Product	Yield (%)	Product	Yield (%)
1	1a	1	CO ₂ H	Н	Н	Н	Н	10a	54	11a	87
2	1c	1	CO_2H	Η	CH_3	Η	Н	10b	44	11b	87
3	1f	1	CO_2CH_3	Н	OCH_3	Н	Н	10c	30	11c	57
4	1 g	1	CO_2CH_3	Br	Н	Н	Н	10d	8	11d	
5	1a	2	CO_2H	Η	Н	Η	Η	10e	55	11e	26
6	1c	2	CO_2H	Н	CH_3	Н	Н	10f	47	11f	44
7	1f	2	CO_2CH_3	Η	OCH_3	Η	Η	10 g	52	11 g	_
8	1 g	2	$\rm CO_2 CH_3$	Br	Н	Н	Н	10 h	3	11 h	

Table 2. The synthesized novel tetracyclic pyrazolo[1,5-a]quinazolines

6,7-Dihydro-*5H,9H*-thieno[3′,4′.3,4]pyrazolo[1,5-a]quinazoline-5one (4a)

White powder, 0.180 g (74%); ¹H NMR (500 MHz, DMSO-d₆): 12.28 (s, 1H, NH), 8.11 (d, 1H, J = 7.5 Hz, Ar-4′H), 7.97 (d, 1H, J = 8.0 Hz, Ar-1′H), 7.84 (t, 1H, J = 8.4 Hz, Ar-2′H), 7.45 (t, 1H, J = 7.5 Hz, Ar-3′H), 4.02 (s, 2H, H-9), 3.83 (s, 2H, H-7); ¹³C NMR (125 MHz, DMSO-d₆): 161.3 (q), 158.8 (q), 138.5 (q), 135.6 (CH), 132.7 (q), 128.6 (CH), 125.5 (CH), 116.2 (q), 114.6 (CH), 104.7 (q), 28.9 (CH₂), 26.8 (CH₂); IR (KBr, cm⁻¹): 2820, 1667. HRMS m/z calcd. for C₁₂H₉N₃OS (M + H)⁺ 244.0546; found 244.0541.

Lactam Reduction

The corresponding indazolo[2,3-*a*]qinazoline-5(6*H*)-one or pyrazolo[1,5-*a*] quinazoline-5-one (1 mmol) was dissolved in dry tetrahydrofurane (30 ml) and at -5° C under a nitrogen atmosphere. BH₃ · THF solution (1 M, 7 ml) was added dropwise. The mixture was stirred at room temperature for 4 h, and then aqueous hydrochloric acid solution (6 M, until no more gas evolved) was added. The pH was adjusted to 13 with 2 M sodium hydroxide solution, and the mixture was extracted with dichloromethane (2 × 200 ml), dried over sodium sulfate, and evaporated. The crude product was purified by column chromatography over silica (eluent: heptane–ethyl acetate 3:1) to yield (26–87%) the product.

6,7-Dihydro-5H,9H-thieno[3',4'.3,4]pyrazolo[1,5-α]quinazoline (5a)

Yield 0.117 g (51%); white powder; ¹H NMR (500 MHz, DMSO-d₆): 7.45 (dm, 1H, J = 8.0 Hz, Ar-1'H), 7.29 (m, 1H, Ar-2'H), 7.23 (dm, 1H, J = 7.3 Hz, Ar-4'H), 7.09 (m, 1H, Ar-3'H), 6.75 (brs, 1H, NH), 4.34 (brs, 2H, H-5), 3.85 (brt, 2H, H-9), 3.68 (brt, 2H, H-7); ¹³C NMR (125 MHz, DMSO-d₆): 160.3 (q), 140.8 (q), 135.9 (q), 128.7 (CH), 126.8 (CH), 124.6 (CH), 121.5 (q), 113.7 (CH), 102.5 (q), 42.8 (CH₂), 28.9 (CH₂), 26.7 (CH₂). IR (KBr, cm⁻¹): 3280, 2916. HRMS m/z calcd. for $C_{12}H_{11}N_{3}S$ (M + H)⁺ 230.0754; found 230.0741.

SUPPLEMENTAL MATERIAL

Full experimental details, assignment, the ¹H and ¹³C NMR spectra, IR spectra, and HRMS details for this article can be accessed on the publisher's website.

REFERENCES

- Baraldi, P. G.; El-Kashef, H.; Manfredini, S.; Pineda de las, I., Maria, J.; Romagnoli, R.; Spalluto, G. Synthesis 1998, 1331–1334.
- 2. Carroll, W. A.; Perez-Medrano, A.; Li, T. PCT Int. Appl. WO 2007056091, 2007.
- Govek, S. P.; Oshiro, G.; Noble, S. A.; Malecha, J. W.; Shiau, A. K. PCT Int. Appl. WO 2008045664, 2008.
- Allen, S.; Andrews, S. W.; Blake, J. F.; Condroski, K. R.; Haas, J.; Huang, L.; Jiang, Y.; Kercher, T.; Kolakowski, G. R.; Seo, J. PCT Int. Appl. WO 2012158413, 2012.

1680

D. KOVÁCS ET AL.

- (a) Padmanabhan, R.; Pattabiraman, N.; Mueller, N.; Nagarajan, K. *PCT Int. Appl.* WO 2010039538, 2010; (b) Gu, B.; Block, T.; Cuconati, A. *PCT Int. Appl.* WO 2007005541, 2007; (c) Gu, B.; Ouzunov, S.; Wang, L.; Mason, P.; Bourne, N.; Cuconati, A.; Block, T. M. *Antiviral Res.* 2006, 70, 39–50.
- 6. Ernst, G. E.; Frietze, W. E.; Simpson, T. R. PCT Int. Appl. WO2006068591, 2006.
- 7. Pfannstiel, K.; Janecke, J. Ber. Chem. Gesellsch. 1942, 75B, 1096-1107.
- 8. Stephenson, E. F. M. Org. Synth. 1949, 29, 54-58.